Charles W. Newton - 10 Feb 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Financial Officer
Signature
/s/ Matthew Lang, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
10 Feb 2025
Transactions value $
$0
Form type
4
Filing time
26 Feb 2025, 19:29:34
Previous filing
12 Jun 2024
Next filing
18 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +113K +186.8% $0.00 173K 10 Feb 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +450K $0.00 450K 10 Feb 2025 Common Stock 450K $0.55 Direct F3
transaction LYEL Option (right to buy) Award $0 +56.3K $0.00 56.3K 10 Feb 2025 Common Stock 56.3K $0.55 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date
F2 Includes 7,800 shares acquired on May 17, 2024 and 3,696 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan.
F3 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
F4 The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.